Open Interest and Volume Dynamics
The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives rose sharply from 21,071 contracts to 28,326, marking an increase of 7,255 contracts or 34.43%. This substantial rise in OI is accompanied by a strong volume of 1,26,433 contracts traded, indicating active participation from both institutional and retail investors. The futures segment alone accounted for a value of approximately ₹21,652.62 lakhs, while options contributed an overwhelming ₹75,338.03 crores, culminating in a total derivatives value of ₹29,985.35 lakhs.
The underlying stock price closed at ₹2,427, touching an intraday high of ₹2,430, reflecting a gap-up opening of 5.62%. This price action, combined with the surge in OI, suggests that market participants are positioning for further upside in the near term.
Market Positioning and Directional Bets
The sharp increase in open interest alongside rising volumes typically signals fresh directional bets rather than mere unwinding of existing positions. In Mankind Pharma’s case, the stock has gained for three consecutive sessions, delivering an 8.18% return over this period. This consistent upward momentum has attracted renewed investor interest, as evidenced by a 23.62% rise in delivery volumes to 3.72 lakh shares on 18 September compared to the five-day average.
Technical indicators further support this bullish stance. The stock trades above its 5-day, 20-day, 100-day, and 200-day moving averages, although it remains slightly below the 50-day average, suggesting a potential short-term consolidation before a sustained rally. The narrow intraday trading range of ₹1.4 today indicates controlled volatility, which often precedes a breakout.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Mankind Pharma outperformed with a 4.43% relative gain compared to the sector’s 1.26% rise. The broader Sensex index advanced by a modest 0.44%, underscoring the stock’s relative strength amid a mixed market environment. With a market capitalisation of ₹98,536 crore, Mankind Pharma is classified as a mid-cap stock, attracting investors seeking growth opportunities in a defensive sector.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Mojo Score and Rating Revision
Mankind Pharma currently holds a Mojo Score of 50.0 with a Mojo Grade of Hold, reflecting a cautious stance by analysts. This represents a downgrade from a previous Buy rating issued on 3 August 2026. The revision likely factors in recent market volatility and the stock’s technical positioning relative to its 50-day moving average. Despite this, the stock’s recent outperformance and rising open interest suggest that investors remain optimistic about its medium-term prospects.
Liquidity and Trading Viability
Liquidity remains robust for Mankind Pharma, with the stock’s traded value supporting a trade size of approximately ₹2.51 crore based on 2% of the five-day average traded value. This level of liquidity is favourable for institutional investors and traders seeking to build or exit sizeable positions without significant market impact.
Implications for Investors
The surge in open interest combined with rising volumes and positive price action indicates that market participants are increasingly bullish on Mankind Pharma. The derivatives market activity suggests fresh long positions are being established, potentially anticipating further gains driven by strong fundamentals and sector tailwinds.
However, the downgrade to a Hold rating and the stock’s position below the 50-day moving average counsel some caution. Investors should monitor whether the stock can sustain its momentum and break decisively above this key technical level to confirm a renewed uptrend.
Considering Mankind Pharma Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this mid-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Outlook and Conclusion
Mankind Pharma’s recent open interest surge in derivatives markets is a clear indicator of increased investor engagement and directional conviction. The stock’s outperformance relative to its sector and the broader market, coupled with rising delivery volumes, supports a constructive near-term outlook. Nevertheless, the Hold rating and technical resistance near the 50-day moving average suggest that investors should remain vigilant for confirmation of sustained momentum.
For investors seeking exposure to the Pharmaceuticals & Biotechnology sector, Mankind Pharma remains a noteworthy candidate, especially given its mid-cap status and strong fundamental base. However, comparative analysis with other top-rated stocks in the sector may reveal better risk-reward opportunities, as highlighted by recent market research.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
